Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation

This research is being done to evaluate Glofitamab by itself or in combination with Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab as possible treatments for Chronic Lymphocytic Leukemia (CLL) that has transformed into Richter's Transformation (RT). The names of the study drugs involved in this research study are: * Glofitamab (a T-cell bispecific humanized monoclonal antibody) * Obinutuzumab (a humanized glycoengineered type II anti-CD20 monoclonal antibody) * Polatuzumab vedotin (an antibody-drug conjugate) * Pirtobrutinib (a selective inhibitor of BTK) * Atezolizumab (a humanized imm

Trial Details

NCT ID
NCT06043674
Phase
PHASE2
Sponsor
Christine Ryan
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Glofitamab
  • Obinutuzumab
  • Polatuzumab Vedotin
  • Atezolizumab
  • Tocilizumab
  • Pirtobrutinib
Locations (sample)
  • Atlanta, Georgia, United States|33.749,-84.38798
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • Chapel Hill, North Carolina, United States|35.9132,-79.05584
  • Columbus, Ohio, United States|39.96118,-82.99879

Key Eligibility Criteria

  • Must have a confirmed diagnosis of chronic lymphocytic leukemia or small lymphocytic lymphoma as per IW-CLL 2018 criteria with biopsy proven transf…
  • Tumor sample may be obtained by core needle or excisional surgical biopsy.
  • A fresh biopsy is encouraged, but an archival sample is acceptable if the following provisions are met: 1) availability of a tumor-containing forma…
  • Biopsy can be obtained up to 3 months prior to first day of treatment.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →